Roswitha Forstpointner

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Roswitha Forstpointner · Blood · 2004 · 579 citations

Treatment of Older Patients with Mantle-Cell Lymphoma

Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine et al. · New England Journal of Medicine · 2012 · 511 citations · Full text

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling et al. · Blood · 2006 · 464 citations · Full text

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A. Herrmann, Eva Hoster, Thomas Zwingers et al. · Journal of Clinical Oncology · 2008 · 394 citations · Full text

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski et al. · The Lancet · 2016 · 390 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10